Effect of siddha medicine in treating Mass in the Breast for Womens

Clinical evaluation of Siddhar kuligai in the management of fibroadenoma of the breast

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/01/022918

Enrollment

Registered

2020-01-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: D249- Benign neoplasm of unspecified breast

Interventions

Intervention1: Siddhar kuligai: Siddhar Kuligai 1 tablet, 56mg bd with Jaggery powder or Butter as oral administration for 3 days Control Intervention1: Not Applicable: Not Applicable

Eligibility

Inclusion criteria

Inclusion criteria: Clinical feautures of Breast lump Painless mobile lump Well localised Axillary lymphadenopathy Skin changes Histologically confirmed Fibroadenoma of breast patients all the patients included in this study were subjected to mammogram and fine needle asiration cytology FNAC for confirmation and differentiation of diagnosis Willing to participate in trail and signing consent by fullfilling the condition of the performa

Exclusion criteria

Exclusion criteria: Male patients Female patients of age below 18 yrs and above 50 yrs Breast carcinoma Patients not willing to take Fine needle aspiration cytology

Design outcomes

Primary

Measure	Time frame
Assessed by mammographic featuresTimepoint: 45 Days	—

Secondary

Measure	Time frame
Reduction in symptoms after treatment Improvement in quality of life of womensTimepoint: 10 days	—

Countries

India

Contacts

Public ContactDr M Meenakshi sundaram

National Institute of Siddha

mmssiddha@gmail.com9940266442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026